Overview

Evaluate SAGE-547 in Patients With Essential Tremor

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Stage 1 is a double-blind, proof-of-concept study designed to evaluate the safety, tolerability, PK, and efficacy of SAGE-547 Injection in male and female patients with essential tremor in the upper limb. Stage 2 is an open-label arm designed to evaluate the safety, tolerability, PK, and effeciveness of SAGE-547 Injection at a higher dose than in Stage 1. Subjects who completed Stage 1 will be invited to participate in Stage 2.
Phase:
Phase 2
Details
Lead Sponsor:
Sage Therapeutics
Treatments:
Brexanolone